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Abstract 
Objective: Aim of the present work is to develop a stability indicating ultra performance liquid 
chromatography (UPLC) method to determine Lidocaine and its degradation impurities in pharmaceutical 
dosage forms.  
Method: Chromatographic separation was achieved by gradient elution on Agilent eclipse plus C18 (100x4.6) 
mm, and 1.8µm column with potassium dihydrogen phosphate buffer (pH 4.50) and acetonitrile within a short 
runtime of 14.0 min. The eluted compounds were  monitored at wavelength of  230 nm using photodiode array  
(PDA) detector, the flow rate was 1.0 mL/min, and the column oven temperature was maintained at 40 ◦C.  
Result: The resolution of Lidocaine and six (potential, bi-products and degradation) impurities was greater 
than 2.0 for all pairs of components. The repeatability and intermediate precision, expressed by the RSD, were 
less than 1.0%. The accuracy and validity of the method were further ascertained by performing recovery 
studies. The specificity of the method was investigated under different stress conditions including hydrolytic, 
oxidative, photolytic and thermal as recommended by ICH guidelines. Relevant degradation was found to take 
place under oxidative condition.  
Conclusion: Method was Robustness against small modification in pH, column oven temperature, flow rate 
and percentage of the mobile phase composition was ascertained. All these results provide that the method has 
stability indicating properties being fit for its intended purpose; it may find application for the routine analysis 
of the related substances of Lidocaine formulations.  
Keywords: Ultra Performance Liquid chromatography (UPLC); Lidocaine; Validation; Stress Degradation 
products 
 
1. Introduction 
Lidocaine Hydrochloride Injection,1 USP is 
chemically designated 2-(diethylamino)-N-(2,6-
dimethylphenyl)-acetamide mono hydrochloride 
monohydrate, commonly used as local 
anesthetic and anti-arrhythmic drug. Lidocaine 
stabilizes the neuronal membrane by inhibiting the 
ionic fluxes required for the initiation and conduction 
of impulses, thereby effecting local anesthetic action. 
It is a white colored powder which is freely soluble in 
water and diethyl ether and insoluble in cold & hot 
water. Lidocaine is having a chemical formula of 
C14H22N2O with molecular weight of 288.82. [Fig-1]. 
UPLC2 is a new separation technique takes advantage 
of technological strides made in particle chemistry 
performance, system optimization, detector design, 
and data processing and control. Using sub-2mm 
particles and mobile phases at high linear velocities, 
and instrumentation that operates at higher pressures 
than those used in HPLC, dramatic increases in 
resolution, sensitivity, and speed of analysis can be 
obtained. This new category of analytical separation 
science retains the practicality and principles of 
HPLC while creating a step function improvement in 
chromatographic performance. UPLC presents the 
ability to extend and expand the utility of separation 
science at a time when many scientists have reached 
separation barriers, pushing the limits of conventional 
HPLC. New chemistry and instrumentation 
technology can provide more information per unit of 
work as UPLC begins to fulfill the promise of 
increased speed, resolution, and sensitivity predicted 
for liquid chromatography 
Figure-1 Structures of Lidocaine & its related impurities: 
 
S.No Name IUPAC Name RR
T 
Mol. 
Weight 
Structure 
1. Lidocaine (C14H22N2O ) 
2-(diethylamino)- 
N-(2,6-
dimethylphenyl)acetamide 
- 234.34 
N H
O
N
 
2. 
5-Hydroxy Methyl 
Furfural 
(C6H6O3) 
5-(hydroxymethyl)-2-
furaldehyde 0.46 126.11 
O
OH
OH
O
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3. 
4-Hydroxy Benzoic 
Acid 
(C7H6O3) 
4-Hydroxybenzoic acid 0.56 138.12 
OH
OH
O
 
4. 
 
Methylparaben 
(C8H8O3) 
Methyl 4-hydroxybenzoate 1.34 152.15 
OH
O O
 
5. 
Lidocaine Impurity 
K 
(C13H20N2O . HCl) 
N-(2,6-Dimethylphenyl)-2-
(ethylmethylamino)acetamid
e Hydrochloride 
1.64  220.32 
N H
O
N C lH
 
6. 
Lidocaine Impurity 
E 
(C20H25N3O2 . HCl) 
2,2'-(Azanediyl)bis[N-(2,6-
dimethylphenyl)-acetamide] 
Hydrochloride 
1.79  339.44 NH
O
NH
O
NH
ClH
7. 2,6-Dimethylaniline (C8H11N) 
2,6-dimethylbenzene-1-
amine 2.01 121.18 
NH2
 
8. 
Lidocaine Impurity 
H 
(C10H12ClNO) 
N-(2,6-Dimethylphenyl) 
chloro acetamide 2.28 197.66 
NH
O
Cl
 
 
To date, all analytical methods described in literature 
[Table-1] include determination of Lidocaine in 
combination of different molecules in biological 
fluids involve liquid chromatography3-4, 
determination of Lidocaine in combination of 
different molecules involve liquid chromatography5-9, 
determination of Lidocaine in combination of 
different molecules involve gas chromatography10 and 
assay methods for determination Lidocaine involves 
UV and liquid chromatography11-12. Literature survey 
shows that no stability indicating method has been 
reported for the determination of Lidocaine and its 
related substances. Hence an attempt was made to 
develop a single method for all paraben, dextrose and 
epinephrine combination formulations which is a 
stability indicating, reliable, accurate and sensitive 
method for the determination of Lidocaine and its 
Degradation Impurities in Pharmaceutical Dosage 
Form. 
 
2.  Experimental 
2.1. Chemicals and Reagents 
Lidocaine (purity 99.0%) and standard materials of 
degradation products were obtained from Hospira 
Health Care India Pvt Ltd, Chennai, India.  
Monobasic potassium phosphate, Orthophosphoric 
acid and acetonitrile were purchased from Ranbaxy 
Chemicals, New Delhi, India.  All chemicals were of 
HPLC grade and used as received.  Water was 
purified by a milli-Q-water purification system 
(Millipore, Bedford, MA, USA) and used for 
preparation of all the solutions. 
2.2   UPLC Instrumentation and Condition 
The analysis was performed using Waters Acquity 
UPLC system (H-Class) equipped with a quaternary 
solvent delivery pump, an auto sampler, and a PDA 
/UV detector.  Data acquisition and processing was 
done by using Empower2 software version FR5 
(Waters Corporation, USA). The chromatographic 
separation was performed using Agilent eclipse plus 
C18 column (100 x 4.6 mm), 1.8 µ particle column.  
The mobile phase was a mixture of mobile phase A 
and mobile phase B.  Mobile phase A was 20mM of 
mono potassium phosphate adjusted to pH 4.5 with 
orthophosphoric acid and acetonitrile was used as 
mobile phase B. The mobile phase A & B were 
pumped through the column at a flow rate of 
1.0mlmin−1 with a gradient elution (Table 2). The 
optimum wavelength selected was 230nm which 
represents the wavelength of maximum response for 
all impurities in order to permit simultaneous 
determination of related impurities of Lidocaine. The 
stressed samples were analyzed using a PDA detector 
covering the range of 200–400 nm. 
Table 1.Comparison of the performance characteristics of the present method with the published 
methods 
S. No        Method   λ ( nm)  Remarks                         Ref 
1. LC-MS/Lidocaine & MEGX     -  Human Plasma                         [3] 
2. LC-MS/Lidocaine      -  Human Plasma                        [4] 
3. HPLC/ Lidocaine & Nystatin                 230  Assay/combinational drugs                       [5] 
4. HPLC/ Lidocaine & Tolperisone    210  Assay/combinational drugs                          [6] 
5. HPLC/ Lidocaine & Tribenoside 254  Assay/combinational drugs                          [7] 
6. HPLC/ Lidocaine & Prilocaine 225  Assay            [8] 
7. HPLC/ Lidocaine & Cetrimonium 208  Assay          [9] 
8. GC/Lidocaine & Bupivacaine   -  Human Plasma                       [10] 
9. UV/Lidocaine   263  Derivatization method                      [11] 
10 HPLC/Lidocaine                  210  Narrow linearity                        [12] 
11. UPLC/ Lidocaine   230  Related substances                               Present work                                      
                                                                                                                Stability Indicating                                                                                         
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2.3 Preparation of buffer, diluent, standard and 
sample solution 
2.3.1. Buffer: About 2.72 g of monobasic phosphate 
phosphate dissolved in 1000 mL of water, adjusted to 
pH 4.5 ± 0.05 with dilute ortho phosphoric acid 
solution was used as buffer(mobile phase A). 
2.3.2. Diluent: The diluent used for the standard and 
sample preparation was a mixture of acetonitrile and 
water in the ratio of 25:75 (v/v). 
2.3.3. Standard: A stock solution of Lidocaine 
Hydrochloride (500 µg/ mL) was prepared by 
dissolving an appropriate amount in the diluent.  
Standard solution containing 2 µg/ mL was prepared 
from this stock solution.   
2.3.4: Sample: 2 mL of Lidocaine injection USP 
solution containing 50000 µg/ mL was dissolved in 50 
mL of diluent to give a solution containing 2000 µg/ 
mL was used as sample solution. 
2.4 Forced degradation sample solution for 
specificity study 
The study was intended to ensure the separation of 
Lidocaine and its degradation impurities. Forced 
degradation study was performed to evaluate the 
stability indicating properties and specificity of the 
method13. As per the ICH guide line Q2(R1)14  
provides the stress conditions to be performed for 
degradation impurities which states that the stress 
samples should be stored under relevant stress 
conditions such as light, heat, humidity, acid/base 
hydrolysis and oxidation. As per the guide line 
multiple stress studies were performed as indicated 
below and they were chromatographed along with an 
un-stressed sample. 
2.4.1.Hydrolytic conditions: acid, base, water 
induced degradation: Solution containing 2mg/mL of 
Lidocaine was treated with 1N HCl, 1N NaOH and 
water respectively.  These samples were refluxed at 
80°C for 5 hrs.   After cooling the solutions were 
neutralized and diluted with diluent.  
2.4.2. Oxidative condition: Hydrogen peroxide-
induced degradation. Solution containing 2mg/mL of 
Lidocaine was treated with 6% w/v H2O2   at 40°C for 
6 hrs was cooled and diluted with diluent. 
2.4.3. Thermal degradation study: The drug solution 
(5mg/mL) was subjected to heat at 105°C for 24 hrs.  
After cooling 2 ml of the above solution was 
transferred in 50 ml volumetric flask, diluted to the 
volume with diluent.  
2.4.4. Photolytic degradation study:  The drug 
solution (5mg/mL) was exposed to the UV light in the 
photolytic chamber for 184 hrs.  2 ml of the above 
solution was transferred in 50 ml volumetric flask, 
diluted to the volume with diluent. 
2.4.5. Humidity degradation study: Metoclopramide 
injection USP (5mg/mL) was subjected 
to25°C/90%RH for 7 days. 2 ml of the above solution 
was transferred in 50 ml volumetric flask, diluted to 
the volume with diluent. 
 
3. Results and discussion 
3.1. Optimization of chromatographic conditions 
3.1.1. Selection of mobile phase: 
Considering that Lidocaine and its related compounds 
acidic buffer in combination of organic modifiers was 
selected, following mobile phases with gradient 
elution were tested, 
1. KH2PO4 · H2O (50mM) of pH 4, 4.5, 5, 6 as 
a buffer in combination with acetonitrile. 
2. (NH4)H2PO4 (50mM) of pH 4, 4.5, 5, 6 as a 
buffer combination with acetonitrile. 
3. KH2PO4 · H2O (20mM) of pH 4, 4.5, 5, 6 as 
a buffer combination with acetonitrile. 
4. KH2PO4 · H2O (20mM) of pH 4, 4.5, 5 as a 
buffer combination with methanol. 
Trails with different combination of buffer and 
organic modifier were performed, Potassium 
phosphate buffer of 50mM strength have given broad 
peak shape with more tailing for Lidocaine and 
Impurity H. To have better tailing trails were 
performed with Ammonium phosphate buffer of 
50mM strength, with Ammonium Phosphate buffer 5-
HMF & 4-HBA were completely merging with each 
other and poor resolution was observed between 
Lidocaine impurity-k & impurity- E. Hence 
KH2PO4·H2O (20mM) as a buffer (pH 4.5) in 
combination with acetonitrile was chosen to improve 
resolution among the impurities and peak shape of 
Lidocaine.  
3.1.2. Selection of stationary phase 
The possible impurities of Lidocaine are very similar 
to Lidocaine. To obtain a good resolution among the 
impurities and main drug substances different 
stationary phases were tested considering; 
a. The feature of stationary phase (C8 and C18). 
b. The particle size of the column (1.7µm and 3µm). 
It is clear from the molecular structure (Fig. 1) that all 
compounds do not possess a functional group which 
can readily ionize indicating non-polar in nature. 
Hence we started the development activity with C8 
stationary phase of various manufacturers using 
different mobile phases. The poor resolution between 
5-HMF and 4-HBA, Lidocaine Impurity-K&E and 
broad peak shape for Lidocaine implies that C8 
stationary phase is not suitable for this application. 
Hence C18 stationary phase was chosen to improve 
resolution among the peaks and peak shape for 
Lidocaine. The development activity was further 
carried out with Waters acquity C18 (100x 2.1) mm 
1.7µ column, the 5-HMF and 4-HBA were 
completely merged with each other; very poor 
resolution was observed between Lidocaine Impurity 
K& E implies that 1.7µm column is not suitable for 
this application. Hence 1.8µm column was used to 
improve resolution among all components, with 
Agilent eclipse plus C18, (100×4.6) mm, 1.8µm 
column the peak shapes and resolution among all 
components was found to be satisfactory. The 
stationary phase is not only the parameter which can 
give better separation among all impurities. Mobile 
phase, pH and organic modifies also plays very 
important role which leads to the best separation. 
Hence in order to get the best separation among the 
impurities and main peaks the further trails were 
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proceeded with Agilent eclipse plus C18, 
100mm×4.6mm, 1.8µm column as stationary phase. 
3.1.3. Influence of organic modifier 
Initially the methanol was used as an organic modifier 
which gives the poor baseline with baseline drift. 
Hence the response for the related compounds was 
reduced. The retention for all impurities was 
increased leading to poor resolution among the peaks. 
To improve the resolution among the peaks and 
response, acetonitrile was tried as an organic 
modifier. The base line was found good and response 
for all components was improved. The peak shape for 
all components was also improved and hence 
acetonitrile was selected as organic modifier. The 
composition of the acetonitrile was altered [Table 2] 
accordingly depending on the molecule and impurity 
to obtain the best separations among the impurities 
and main peaks. 
 
Table 2: Mobile phase program for gradient elution: 
 
       Time (min)     Flow (mlmin−1)       Solvent A (%)       Solvent B (%) 
               0   1.0    90   10  
 4   1.0    70   30  
 5   1.0    68   32 
11   1.0    65   35 
12   1.0    90   10 
14   1.0    90   10 
Solvent A: potassium dihydrogen phosphate buffer (pH 4.5); solvent B: Acetonitrile 
 
3.1.4. Influence of pH of mobile phase buffer 
Different pH values of the mobile phase were 
checked to establish the optimum separation and the 
highest analytical sensitivity for Lidocaine and its 
degradation products. The mobile phase was buffered 
because of the existence of ionizable groups in the 
chemical structure of the drug, which could ionize at 
different pH values. The pH values tested were 4.0, 
4.5 and 5.0. Finally, the best results were obtained at 
pH 4.5 ±0.1 by adjusting with diluted ortho 
phosphoric solution. The choice of this mobile phase 
is justified by the excellent symmetry of the peaks 
and adequate retention times of Lidocaine and its 
degradants. 
3.1.5. Selection of wavelength 
Based on the spectra [Fig. 2] of Lidocaine and its 
related substances 230 nm was selected as detection 
wavelength for the method.  
Figure- 2 Spectra of Lidocaine and its related 
impurities: 
 
 
3.1.6. Flow rate optimization 
 Different mobile phase flow rates (0.8, 1.0and 1.2 
mL min-1) were investigated. The optimum flow rate 
for which the column plate number was maximum, 
with the best resolution between all compounds and 
with a shortest runtime of 14 min observed was 1.0 
mL min-1. 
3.1.7. Column temperature optimization 
Column thermostat temperatures were used at 35ºC, 
40ºC and 45ºC for better peak shapes, baseline and 
resolution. At the column oven temperature of 40ºC 
the finest baseline resolution was observed between 
all the components 
After an extensive study, the method has been 
finalized on Agilent eclipse plus C18, 
100mm×4.6mm, 1.8µm columns using variable 
composition of solvent A: KH2PO4.H2O (20mM), pH 
4.5 with diluted ortho phosphoric acid and solvent B: 
acetonitrile as mobile phase. The mobile phase 
pumped through the column with gradient elution 
[Table 2] at a flow rate of 1.0 ml min−1 and column 
compartment temperature kept at 40 ◦C.  Depending 
on the λ max [Fig. 2] of the Lidocaine and its related 
impurities the detector response for all the 
components found maximum at 230 nm, hence the 
typical chromatogram was recorded at this 
wavelength. The typical UPLC chromatograms (Fig. 
3) represent the satisfactory separation of all 
components among each other. 
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Figure -3 Impurity spiked chromatogram Lidocaine: 
 
Fig-3: Overlay of Blank, Placebo, Diluted standard and Impurity Spiked chromatogram 
  
3.2. Results of specificity/ Force degradation 
study: 
The peak purity indices for the analytes in stressed 
solutions were determined with PDA detector under 
optimized chromatographic conditions found to be 
better (purity angle < purity threshold) indicating that 
no additional peaks were co-eluting with the analytes 
and evidencing the ability of the method to assess  
unequivocally the analyte of interest in the presence 
of potential interference. Baseline resolution was 
achieved for all investigated compounds. The FDA 
guidelines indicated that well separated peaks, with 
resolution, Rs > 2 between the peak of interest and the 
closest eluting peak, are reliable for the 
quantification15. Degradation was not observed in a 
Lidocaine sample during photolytic, hydrolytic, 
thermal and humidity stress.  About 9.25% of 
degradation was observed in oxidative stress. The 
method is linear in the tested range. Peaks meet this 
specification, visibly confirmed in Fig 4.   
Figure 4 Specificity / Force Degradation 
Chromatograms: 
 
Figure 4.1: Acid Stress: 
 
Figure 4.2: Base Stress: 
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Figure 4.3: Water Stress: 
 
 
Figure 4.4: Peroxy Stress: 
 
Figure 4.1.4: Purity plot for Peroxy Stress: 
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Figure 4.5: Thermal Stress: 
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Figure 4.6: Photolytic Stress: 
 
 
Figure 4.7: Humidity Stress: 
 
 
Peak purity results from the PDA detector for the 
peaks produced by the degradation of Lidocaine, 
confirmed that all these peaks were homogenous and 
pure for all the stressed samples analysed (Table 3).   
The mass balance (% assay + % sum of all 
compounds + % sum of all degradants) results were 
calculated for all of the stressed samples and were 
found to be more than 98 % (Table 3).   The purity 
and assay of Lidocaine was unaffected by the 
presence of its impurities and degradation products, 
which confirms the stability-indicating power of the 
developed method.    
 
Table 3: Forced Degradation Studies of Lidocaine & its related substances: 
 
Condition     %degradation      Purity Angle         Purity Threshold     Purity Flag          Mass Balance 
Acid  0.02   3.604  5.317  No  98.2%  
Base   0.03   4.819  5.5528  No  99.3%  
Water  0.01   4.124  5.357  No  100.2% 
Oxidation 9.25   3.730  5.485  No  97.8%             
Thermal                0.01   4.128  5.826  No  99.8%  
Photolytic  0.01   2.869  3.852  No  100.6%            
Humidity 0.02   4.576  5.128  No  100.4%              
 
3.3. Results of method validation studies 
3.3.1. Method validation 
The optimized RP-UPLC method validated according 
to ICH guideline Q2 (R1), with respect to specificity, 
accuracy, precision (repeatability and intermediate 
precision), linearity, range and robustness. System 
suitability features were also assessed. 
3.3.2. Method precision 
ICH (International Conference on Harmonization of 
technical Requirements for Registration of 
Pharmaceuticals for Human Use) considers 
ruggedness as the method reproducibility and 
intermediate precision. The method reproducibility 
was determined from the %RSD. The intermediate 
precision was determined from the difference in the 
average recoveries and the difference in the %RSD of 
the recoveries among the three analysts. The RSD of 
the area of Lidocaine related compounds were within 
0.4%.  The RSD of results obtained in intermediate 
precision studies was within 1.0%. The results for all 
the tested compounds were listed in Table 4 reveal 
that the method has good reproducibility and 
intermediate precision. 
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Table 4   Intraday – Inter day precision studies of Lidocaine Related substances 
 
Name of impurity       Intraday precision Inter day precision 
                                 *% of impurity                 *%RSD                         *% of impurity                       *%RSD  
5-HMF                 0.244          0.3                   0.245      0.9  
4-HBA   0.221          0.1                   0.225      0.2 
IMP-K   0.217          0.3                   0.215      0.6 
IMP-E   0.223          0.0                   0.220   0.9 
2,6-DMA  0.215          0.2                   0.221   0.8 
IMP-H   0.231          0.2                   0.230   0.5 
 *Mean of six replicates.  
3.3.3. Determination of limit of quantification and 
detection (LOQ and LOD) 
As per the guideline ICH Q2(R1), LOD is defined as 
the detection limit of an individual analytical 
procedure is the lowest amount of analyte in a sample 
which can be detected but not necessarily quantitated 
as an exact value. The quantitation limit of an 
individual analytical procedure is the lowest amount 
of analyte in  a sample which can be quantitatively 
determined with suitable precision and accuracy. The 
quantitation limit is a parameter of quantitative assays 
for low levels of compounds in sample  matrices, and 
is used particularly for the determination of impurities 
and/or degradation  products. 
The linearity performed above, used for the 
determination of limit of quantification and detection. 
Residual standard deviation (σ) method was applied 
and the LOQ and LOD values were predicted using 
following formulas (a) and (b) and established the 
precision at these predicted levels. The results are 
tabulated in Table 5  
                          10 σ 
LOQ        =   ------------                    --------------------------------------------------------- (a) 
                           S 
                          3.3 σ 
LOD        =   ------------                    --------------------------------------------------------- (b) 
                           S 
Where σ = standard deviation of response and S = slope of the calibration curve 
Table 5   Limit of quantification & Limit of detection 
Name of impurity  Limit of Quantification   Limit of Detection  
         Conc.µg/mL      % of impurity                   % RSD         Conc.µg/mL     % of impurity      % RSD  
5-HMF 0.108 0.010    1.6  0.036 0.003 4.9 
4-HBA 0.075  0.007 2.8 0.025 0.002 4.8 
IMP-K                  0.118                    0.011 1.8 0.039 0.001  2.9 
IMP-E 0.109 0.011 1.4 0.036 0.001 4.1 
2, 6-DMA 0.105 0.010 1.9 0.035 0.001 4.7 
IMP-H 0.112 0.012 2.0 0.037 0.002 3.6 
 
3.3.4. Accuracy 
Accuracy was evaluated by the simultaneous 
determination of analytes in solution prepared by 
standard addition method. The experiment was 
carried out by adding known amount of each related 
impurities corresponding to different concentration 
levels  of  LOQ,  50 %,  75 %, 100 % and 150 % of 
the specification level in sample solution. The 
samples were prepared in triplicate at each level. The 
quantification of added analyte was carried out by 
using an external standard of corresponding main 
drug prepared at the analytical concentration. The 
experimental results revealed that approximately 97–
103% recoveries were obtained for all the 
investigated related compounds. Therefore, based on 
the recovery data (Table 6) the estimation of related 
compounds that are prescribed in this report has been 
demonstrated to be accurate for intended purpose and 
is adequate for routine analysis. 
 
Table 6   Accuracy study of Lidocaine Related substances 
 
          5-HMF                                    4-HBA                                     IMP-K  
               Add  Rec % R  Add Rec %R  Add  Rec         %R  
LOQ  0.108 0.108 100.2  0.075 0.074  98.9     0.114 0.114  99.6  
50 1.083 1.111 102.6    1.052 1.090 103.6   1.035     1.006  97.2         
75 1.513 1.507  99.6  1.468 1.456  99.2  1.446 1.481     102.4  
100 2.146 2.099  97.8   2.073 2.042  98.5   2.071 2.098     101.3  
150 3.005 3.014 100.3     3.030     3.085 101.8  3.034  2.995  98.7   
Add-µg/mL added; Rec- µg/mL recovered; %R- %recovery  
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       IMP-E          2,6-DMA               IMP-H  
          Add Rec % R  Add Rec %R  Add Rec %  R 
LOQ 0.109 0.112 102.5  0.105 0.103  98.1  0.112 0.109  97.4  
50 1.094  1.096 100.2     1.098 1.082  98.5  1.084 1.054  97.2         
75 1.532 1.529  99.8     1.456 1.460 100.3  1.562 1.574 100.8  
100 2.188 2.151  98.3    2.089 2.110 101.0  2.075 2.102 101.3  
150 3.052 2.976  97.5     3.042 3.033   99.7  3.032 3.114 102.7   
Add-µg/mL added; Rec- µg/mL recovered; %R- %recovery 
3.3.5. Linearity and range 
The linearity of an analytical procedure is its ability to 
obtain test results which are directly proportional to 
the concentration of the analyte in the sample.  The 
linearity of the test method was established from the 
LOQ to 150% of the test concentration for Lidocaine 
and its related substances. The plots of area under the 
curve (AUC) of the peak responses of the analytes 
against their corresponding concentrations, they fitted 
straight lines responding to equations. The y-
intercepts were close to zero with their confidence 
intervals containing the origin. The correlation 
coefficient (r) exceeds 0.98, the acceptance threshold 
suggested for linearity of procedures for the 
determination of impurity content in bulk drug and it 
is found to be 0.9999 in all the cases. Results were 
represented in Table 7.  
Table 7   Linearity study of Lidocaine Related substances 
      5-HMF    4-HBA                      IMP-K                     IMP-E                   2,6-DMA               IMP-H 
                Add  Rec Add  Rec Add  Rec  Add  Rec Add  Rec Add        Rec 
LOQ 0.108 0.109 0.075 0.074 0.114 0.118 0.109 0.106 0.105 0.109 0.112    0.110 
50 1.083 1.100 1.052 1.070 1.035 1.080 1.094 1.132 1.098 1.112 1.084    1.082 
75 1.513 1.543 1.468 1.471 1.446 1.432 1.532 1.543 1.456 1.468 1.562    1.702 
100 2.146 2.195 2.073 2.095 2.071 2.079 2.188 2.190 2.089 2.096 2.075    2.087 
150 3.005 3.025 3.030 3.030 3.034 3.039 3.052 3.048 3.042 3.056 3.032    3.032 
r                    0.999914               0.999958                  0.999902                  0.999935                  0.999925              0.999919  
Add-µg/mL added; Rec- µg/mL recovered; r= correlation coefficient. 
3.3.6. Robustness 
In order to demonstrate the robustness of the method, 
system suitability parameters were verified by making 
deliberate change in the chromatographic conditions, 
i.e., change in the flow rate by ±0.2mL/min, change 
in column oven temperature by ±5°C and change in 
organic composition of mobile phase by ±2% 
absolute. The sample spiked with all known 
impurities at impurity tolerance level was injected and 
the resolution among the impurities was monitored. 
The method was demonstrated to be robust over an 
acceptable working range of its UPLC operational 
conditions. The results are tabulated in Table 8.  
 
Table-8: Robustness study of Lidocaine Related substances 
Parameter     RRT of Impurity 
      5-HMF   4-HBA       IMP-K                IMP-E          2, 6-DMA             IMP-H 
Column Temp(°C) 
35      0.46    0.57   1.65  1.79  2.01        2.28  
40     0.46    0.56   1.65  1.79  2.01        2.27 
 45     0.47    0.57   1.66  1.80  2.00        2.29 
pH of buffer 
 4.3     0.47    0.54   1.65  1.81  2.04        2.26 
 4.5     0.46    0.56   1.64  1.80  2.02              2.28   
 4.7     0.49    0.55   1.66  1.80  2.00        2.28 
Flow rate (mL min-1)  
0.8    0.46    0.56   1.64  1.78  2.01        2.27 
 1.0    0.46    0.57   1.64  1.79  2.01        2.27 
 1.2    0.48    0.59   1.65  1.78  2.02               2.28 
 
3.3.7. Solution stability and mobile phase stability 
The  RSD (%)  values of all the six impurities 
during solution stability and mobile phase stability 
experiments was within 1.0%.  No significant change 
was observed in the content of impurities during 
solution stability and mobile phase stability 
experiments confirm that sample solutions and mobile 
phase used during the study were stable up to 48 
hours. 
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4. Conclusion 
A stability study was carried out and an efficient 
UPLC method for the quantification of related 
substances of Lidocaine in drug product was 
developed and validated. The results of the stress 
testing of the drug, undertaken according to the ICH 
guidelines, revealed the stability indicating nature 
of the Method.  
Validation experiments provided proof that the UPLC 
analytical method is linear in the proposed working 
range as well as accurate, precise (repeatability and 
intermediate precision levels) and specific, being able 
to separate the main drug from its degradation 
products. The proposed method was also found to be 
robust with respect to flow rate, column oven 
temperature and composition of mobile phase. Due to 
these characteristics, the method has stability 
indicating properties being fit for its intended 
purpose; it may find application for the routine 
analysis of the related substances of Lidocaine 
formulations. 
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